Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic
Needham: Reiterates the Trevi Therapeutics (TRVI.US) rating, adjusted from buy to buy, with a target price of $8.00.
Needham: Reiterates the Trevi Therapeutics (TRVI.US) rating, adjusted from buy to buy, with a target price of $8.00.
Trevi Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 155.18% Needham → $8 Reiterates Buy → Buy 03/21/2024 187.08% Oppenheimer $9 → $9 Maintains Outp
CALM,PLAY and VNDA Are Among After Hour Movers
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Oculis Holding (OCS) and Quanterix (QTRX)
Buy Rating for Trevi Therapeutics Anchored on Haduvio's Clinical Promise and Market Potential
Trevi Therapeutics Price Target Maintained With a $9.00/Share by Oppenheimer
Trevi Therapeutics Price Target Maintained With a $9.00/Share by Oppenheimer
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vor Biopharma (VOR), Roche Holding AG (OtherRHHVF) and Trevi Therapeutics (TRVI)
Trevi Therapeutics (TRVI) Receives a Buy From Stifel Nicolaus
Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target
Needham analyst Serge Belanger reiterates Trevi Therapeutics with a Buy and maintains $8 price target.
Analysts' Top Healthcare Picks: Trevi Therapeutics (TRVI), Walgreens Boots Alliance (WBA)
Q4 2023 Trevi Therapeutics Inc Earnings Call
Earnings Call Summary | Trevi Therapeutics(TRVI.US) Q4 2023 Earnings Conference
The following is a summary of the Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript:Financial Performance:No financial performance details provided for this period.Business Progress:Tre
Trevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trials
ARAY, AXTI and LZ Are Among After Hour Movers
Trevi Therapeutics: Q4 Earnings Insights
Trevi Therapeutics (NASDAQ:TRVI) reported its Q4 earnings results on Wednesday, March 20, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsTrevi Therapeutics beat est
Trevi Therapeutics Q4 2023 GAAP EPS $(0.08) Beats $(0.09) Estimate
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent.
Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates PR Newswire NEW HAVEN, Conn., March 20, 2024 Reaffirms guidance for the Phase 2a RIVER tr
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data expected in the second half of 2024 Enrollment progressing in the Phase 2b CORAL dose-ranging trial of Had
Earnings Outlook For Trevi Therapeutics
Trevi Therapeutics (NASDAQ:TRVI) is set to give its latest quarterly earnings report on Wednesday, 2024-03-20. Here's what investors need to know before the announcement.Analysts estimate that Trevi T
No Data